|Bid||32.73 x 100|
|Ask||33.00 x 300|
|Day's Range||32.32 - 32.87|
|52 Week Range||29.83 - 35.38|
|PE Ratio (TTM)||27.58|
|Dividend & Yield||1.28 (3.92%)|
|1y Target Est||N/A|
India has granted Pfizer Inc a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the treatment out of reach of thousands in poorer nations. The decision by India's patent office bars other companies from making cheaper copies of the vaccine and allows Pfizer to exclusively sell it in India until 2026. It's a big victory for the U.S. drugmaker in a market that has the world's largest number of pneumonia cases, a lung disease that kills nearly a million children a year globally.
Pfizer, GlaxoSmithKline, and Novo Nordisk all offer up temptingly high yields. Here's why they're worth putting on your radar.
There's good reason why Pfizer, Cisco Systems, and Diageo can work for you in your retirement.